2025: Cure Parkinson's research highlights from the last year and insights for the year ahead
2024 was another busy year for the research team at Cure Parkinson’s; from the results publication of the phase 2 clinical trial of lixisenatide to the funding of new pre-clinical projects, Cure Parkinson’s has not stopped in its mission to slow, stop or reverse Parkinson’s....
Learn more
Van Andel Institute: Virtual public lecture series
This informative event featured presentations and a Q&A session with international Parkinson’s disease experts including Cure Parkinson’s Director of Research, Dr Richard Wyse and Deputy Director of Research, Dr Simon Stott.
A skin test for Parkinson’s
Researchers have been investigating a waxy substance on our skin (called sebum) as a possible way of determining who does or does not have Parkinson’s.
Results of the MOVES-PD trial announced
MOVES-PD is a global phase 2 study to assess the efficacy and safety of the drug venglustat in Parkinson’s patients who have a GBA-1 gene mutation. Sanofi designed the venglustat clinical trial to assess changes in the course of the disease.
Further data on the relationship between diabetes and Parkinson’s
New research has found that there is convincing evidence that Type 2 diabetes is associated with a greater risk of Parkinson’s, but may in turn allow for better management of the disease.
Rheumatoid arthritis and Parkinson’s
Recently, researchers have asked whether there is an association between Parkinson’s and rheumatoid arthritis: Could people with rheumatoid arthritis be at higher risk of developing Parkinson’s?